Insider Transactions in Q1 2023 at Rubius Therapeutics, Inc. (RUBY)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 24
2023
|
Dannielle Appelhans CEO and President |
SELL
Open market or private sale
|
Direct |
10,385
-100.0%
|
$0
$0.13 P/Share
|
|
Feb 01
2023
|
Dannielle Appelhans CEO and President |
SELL
Open market or private sale
|
Direct |
3,878
-27.19%
|
$0
$0.25 P/Share
|
|
Feb 01
2023
|
Pablo J Cagnoni Director |
SELL
Open market or private sale
|
Direct |
8,448
-11.34%
|
$0
$0.25 P/Share
|
|
Jan 31
2023
|
Dannielle Appelhans CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+34.46%
|
-
|
|
Jan 31
2023
|
Laurence A. Turka Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,593
-12.36%
|
$0
$0.24 P/Share
|
|
Jan 31
2023
|
Laurence A. Turka Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,625
+29.13%
|
-
|
|
Jan 31
2023
|
Pablo J Cagnoni Director |
SELL
Open market or private sale
|
Direct |
7,240
-8.85%
|
$0
$0.24 P/Share
|
|
Jan 31
2023
|
Pablo J Cagnoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+23.41%
|
-
|
|
Jan 29
2023
|
Laurence A. Turka Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,438
+37.57%
|
-
|
|
Jan 29
2023
|
Pablo J Cagnoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,250
+27.24%
|
-
|